Article thumbnail

LARGE Expression Augments the Glycosylation of Glycoproteins in Addition to α-Dystroglycan Conferring Laminin Binding

By Zhen Zhang, Peng Zhang and Huaiyu Hu

Abstract

Mutations in genes encoding glycosyltransferases (and presumed glycosyltransferases) that affect glycosylation and extracellular matrix binding activity of α-dystroglycan (α-DG) cause congenital muscular dystrophies (CMDs) with central nervous system manifestations. Among the identified genes, LARGE is of particular interest because its overexpression rescues glycosylation defects of α-DG in mutations of not only LARGE but also other CMD-causing genes and restores laminin binding activity of α-DG. It is not known whether LARGE protein glycosylates other proteins in addition to α-DG. In this study, we overexpressed LARGE in DG-deficient cells and analyzed glycosylated proteins by Western blot analysis. Surprisingly, overexpression of LARGE in α-DG-deficient cells led to glycosylation dependent IIH6C4 and VIA4-1 immunoreactivity, despite the prevailing view that these antibodies only recognize glycosylated α-DG. Furthermore, the hyperglycosylated proteins in LARGE-overexpressing cells demonstrated the functional capacity to bind the extracellular matrix molecule laminin and promote laminin assembly at the cell surface, an effect that was blocked by IIH6C4 antibodies. These results indicate that overexpression of LARGE catalyzes the glycosylation of at least one other glycoprotein in addition to α-DG, and that this glycosylation(s) promotes laminin binding activity

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3080415
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose beta1,2-Nacetylglucosaminyltransferase (POMGnT1).
  2. (2003). A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype.
  3. (1993). A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin.
  4. (2001). A stoichiometric complex of neurexins and dystroglycan in brain.
  5. (1999). alpha-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability.
  6. (1998). An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy.
  7. (1999). Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.
  8. (2002). Cloning and expression of a novel UDPGlcNAc:alpha-D-mannoside beta1,2-N-acetylglucosaminyltransferase homoloProtein Glycosylation by
  9. (2002). Deficiency of alpha-dystroglycan in muscle-eye-brain disease.
  10. (2002). Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy.
  11. (1998). Dell A
  12. (2004). Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity.
  13. (1998). Detection of O-mannosyl glycans in rabbit skeletal muscle alpha-dystroglycan.
  14. (1999). Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety.
  15. (1994). Dystroglycan is a binding protein of laminin and merosin in peripheral nerve.
  16. (1996). Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane.
  17. (1994). Dystroglycanalpha, a dystrophin-associated glycoprotein, is a functional agrin receptor.
  18. (1999). Dystrophic phenotype induced in vitro by antibody blockade of muscle alphadystroglycan-laminin interaction.
  19. (2003). Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development.
  20. (1999). High prevalence of 2-mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain glycopeptides by reductive alkaline hydrolysis.
  21. (1995). Identification and functional characterization of mouse CD29 with a mAb.
  22. (1986). Identification of an Oglycosidic mannose-linked sialylated tetrasaccharide and keratan sulfate oligosaccharides in the chondroitin sulfate proteoglycan of brain.
  23. (1993). Laminin-binding protein 120 from brain is closely related to the dystrophinassociated glycoprotein, dystroglycan, and binds with high affinity to the major heparin binding domain of laminin.
  24. (2004). LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies.
  25. (2005). LARGE2 facilitates the maturation of alpha-dystroglycan more effectively than LARGE.
  26. (2005). Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy.
  27. (2009). Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE.
  28. (1991). Membrane organization of the dystrophinglycoprotein complex.
  29. (2003). Molecular cloning and characterization of human GnT-IX, a novel beta1,6-N-acetylglucosaminyltransferase that is specifically expressed in the brain.
  30. (2004). Molecular recognition by LARGE is essential for expression of functional dystroglycan.
  31. (2005). Mouse large can modify complex N- and mucin Oglycans on alpha-dystroglycan to induce laminin binding.
  32. (2001). Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1.
  33. (2001). Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse.
  34. (2009). Mutational and functional analysis of Large in a novel CHO glycosylation mutant.
  35. (2005). Mutations in POMT1 are found in a minority of patients with Walker-Warburg syndrome.
  36. (2004). Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome.
  37. (2001). Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C.
  38. (2003). Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.
  39. (2002). Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome.
  40. (2004). N-Acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-Man alpha 1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan.
  41. (2001). NMR studies of mannitolterminating oligosaccharides derived by reductive alkaline hydrolysis from brain glycoproteins.
  42. (1979). Novel mannitolcontaining oligosaccharides obtained by mild alkaline borohydride treatment of a chondroitin sulfate proteoglycan from brain.
  43. (2010). Omannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.
  44. (2006). Physical and functional association of human protein
  45. (2011). Pikachurin interaction with dystroglycan is diminished by defective O-mannosyl glycosylation in congenital muscular dystrophy models and rescued by LARGE overexpression.
  46. (2008). Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation.
  47. (2000). Polysialic acid regulates chain formation by migrating olfactory interneuron precursors.
  48. (2004). POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG.
  49. (2005). POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.
  50. (2010). Post-translational maturation of dystroglycan is necessary for pikachurin binding and ribbon synaptic localization.
  51. (2002). Posttranslational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies.
  52. (1992). Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix.
  53. (1995). Purification of cranin, a laminin binding membrane protein. Identity with dystroglycan and reassessment of its carbohydrate moieties.
  54. (2002). Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye - brain disorders.
  55. (1997). Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin.
  56. (2001). The complexities of dystroglycan.
  57. (1999). The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family.
  58. (1998). The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction.
  59. (2004). The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains.
  60. (2009). Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.